Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase III for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase III drugs for Atopic Dermatitis (Atopic Eczema) have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Jaktinib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Jaktinib hydrochloride overview
Jaktinib is under development for the treatment of graft versus host disease, rheumatoid arthritis, plaque psoriasis, idiopathic pulmonary fibrosis, autoimmune disorders, novel coronavirus pneumonia (COVID-19), myelofibrosis including primary myelofibrosis (factor PMF), polycythemia vera myelofibrosis post (Post-PV-MF) or essential thrombocytosis myelofibrosis (Post-ET-MF), alopecia areata and atopic dermatitis. The drug candidate is formulated as a tablet and cream form which is administered through oral and topical route. It acts by targeting tyrosine protein kinase JAK1, JAK2 and JAK3. It is chemically new drug. The drug candidate was also under development for autoimmune disease lupus, myelodysplastic syndrome.
For a complete picture of Jaktinib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.